Agreement will place Quantel Medical SupraScan lasers in 53 military hospitals across India
CLERMONT-FERRAND, France - Wednesday, March 30th 2016 [ME NewsWire]
(BUSINESS WIRE)-- Quantel Medical (Quantel), a global ophthalmic medical device company dedicated to developing leading technologies to improve the diagnosis and treatment of ocular diseases, announced it has been awarded a €3 million competitive tender for ophthalmic laser equipment.
Under the terms of a supply agreement signed by the Directorate General of Armed Forces Medical Services of the Indian Ministry of Defense, Quantel Medical will provide 61 photocoagulator lasers for use in 53 military hospitals across India. The 532nm Supra with Suprascan is a diverse and versatile laser platform capable of delivering a number of Multispot and MicroPulse® patterns.
“Diabetes is extremely prevalent in India, affecting more than 62 million individuals, or about 7% of the adult population. It is well known that uncontrolled diabetes can be a precursor for the development of vision-related complications, including diabetic retinopathy and diabetic macular edema, both of which are very common in India. One study suggested that as many as 20% of individuals with diabetes in India are affected by diabetic retinopathy,” said Jean‐Marc Gendre, CEO of Quantel Medical.
“This agreement will put an extremely powerful treatment option in the hands of physicians who treat patients with diabetic eye disease. It is a platform that can be adapted to use for other applications as well. Laser treatment of diabetes is in many cases as effective as medical treatment, and it is demonstrated to be much more cost effective,” added Jean‐Marc Gendre, CEO of Quantel Medical.
About Quantel Medical
Founded in 1993 and headquartered in Clermont-Ferrand, France, Quantel Medical is a global ophthalmic medical device company dedicated to developing leading technologies to improve the diagnosis and treatment of ocular diseases. Quantel Medical has a strong emphasis in research and development, resulting in many first-to-market product introductions and a comprehensive product portfolio of diagnostic ultrasound, surgical lasers and a range of disposable products for ophthalmologists. These products are available through direct sales operations in the U.S. and France, and through 80 independent distributors in over 110 countries. Quantel Medical is a division of Quantel (QUA:EN), a world-wide leader in the development of solid state lasers for scientific and industrial applications. For more information, please visit www.quantel-medical.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160329006569/en/
Contacts
Quantel Medical
Company contact:
Jan-Philippe Heydel
Jan-Philippe.Heydel@quantel-medical.fr
Media contact:
Delphine Southon
Delphine.Southon@quantel-medical.fr
Permalink: http://me-newswire.net/news/17450/en
CLERMONT-FERRAND, France - Wednesday, March 30th 2016 [ME NewsWire]
(BUSINESS WIRE)-- Quantel Medical (Quantel), a global ophthalmic medical device company dedicated to developing leading technologies to improve the diagnosis and treatment of ocular diseases, announced it has been awarded a €3 million competitive tender for ophthalmic laser equipment.
Under the terms of a supply agreement signed by the Directorate General of Armed Forces Medical Services of the Indian Ministry of Defense, Quantel Medical will provide 61 photocoagulator lasers for use in 53 military hospitals across India. The 532nm Supra with Suprascan is a diverse and versatile laser platform capable of delivering a number of Multispot and MicroPulse® patterns.
“Diabetes is extremely prevalent in India, affecting more than 62 million individuals, or about 7% of the adult population. It is well known that uncontrolled diabetes can be a precursor for the development of vision-related complications, including diabetic retinopathy and diabetic macular edema, both of which are very common in India. One study suggested that as many as 20% of individuals with diabetes in India are affected by diabetic retinopathy,” said Jean‐Marc Gendre, CEO of Quantel Medical.
“This agreement will put an extremely powerful treatment option in the hands of physicians who treat patients with diabetic eye disease. It is a platform that can be adapted to use for other applications as well. Laser treatment of diabetes is in many cases as effective as medical treatment, and it is demonstrated to be much more cost effective,” added Jean‐Marc Gendre, CEO of Quantel Medical.
About Quantel Medical
Founded in 1993 and headquartered in Clermont-Ferrand, France, Quantel Medical is a global ophthalmic medical device company dedicated to developing leading technologies to improve the diagnosis and treatment of ocular diseases. Quantel Medical has a strong emphasis in research and development, resulting in many first-to-market product introductions and a comprehensive product portfolio of diagnostic ultrasound, surgical lasers and a range of disposable products for ophthalmologists. These products are available through direct sales operations in the U.S. and France, and through 80 independent distributors in over 110 countries. Quantel Medical is a division of Quantel (QUA:EN), a world-wide leader in the development of solid state lasers for scientific and industrial applications. For more information, please visit www.quantel-medical.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160329006569/en/
Contacts
Quantel Medical
Company contact:
Jan-Philippe Heydel
Jan-Philippe.Heydel@quantel-medical.fr
Media contact:
Delphine Southon
Delphine.Southon@quantel-medical.fr
Permalink: http://me-newswire.net/news/17450/en